50.
Binding-interaction prediction of RNA-binding ligands. Tuccinardi T. Future Med Chem. 2011, 3(6):723-733.
49.
Different Binding Modes of Structurally Diverse Ligands for Human D3DAR. Ortore G, Tuccinardi T, Orlandini E, Martinelli A. J Chem Inf Model. 2010, 50(12):2162-2175.
48.
Synthesis of heterocycle-based analogs of resveratrol and their antitumor and vasorelaxing properties. Bertini S, Calderone V, Carboni I, Maffei R, Martelli A, Martinelli A, Minutolo F, Rajabi M, Testai L, Tuccinardi T, Ghidoni R, Macchia M. Bioorg Med Chem. 2010, 18(18):6715-6724.
47.
Adenosine Receptor Ligands in Clinical Trials. Rizzolio F, La Montagna R, Tuccinardi T, Russo G, Caputi M, Giordano A. Curr Top Med Chem. 2010; 10(10):1036-1045.
46.
New Tris(hydroxypyridinones) as Iron and Aluminium Sequestering Agents: Synthesis, Complexation and In Vivo Studies. Chaves S, Marques SM, Matos AM, Nunes A, Gano L, Tuccinardi T, Martinelli A, Santos MA. Chemistry – A European Journal 2010, 16(34):10535-10545.
45.
Protein Kinases: Docking and Homology Modeling Reliability. Tuccinardi T, Botta M, Giordano A, Martinelli A. J Chem Inf Model. 2010, 50(8):1432-1441.
44.
CDK inhibitors: from the bench to clinical trials. Rizzolio F, Tuccinardi T, Caligiuri I, Lucchetti C, Giordano A. Curr. Drug Targets. 2010;11(3):279-290.
43.
Design, Synthesis, Biological Evaluation, and NMR Studies of a New Series of Arylsulfones As Selective and Potent Matrix Metalloproteinase-12 Inhibitors. Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D’Amelio N, Maiocchi A, Uggeri F, Rossello A. J Med Chem 2009, 52(20):6347-6361.
42.
A virtual screening study of the 18-kDa translocator protein using pharmacophore models combined with 3D-QSAR studies. Tuccinardi T, Taliani S, Bellandi M, Da Settimo F, Da Pozzo E, Martini C, Martinelli A. ChemMedChem 2009, 4(10):1686-1694.
41.
N-O-Isopropyl Sulfonamido-Based Hydroxamates: Design, Synthesis and Biological Evaluation of Selective Matrix Metalloproteinase-13 Inhibitors as Potential Therapeutic Agents for Osteoarthritis. Nuti E, Casalini F, Avramova SI, Santamaria S, Cercignani G, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Tuccinardi T, Martinelli A, Lim NH, Visse R, Nagase H, Rossello A. J Med Chem 2009, 52(15):4757–4773.
40.
Multitemplate Alignment Method for the Development of a Reliable 3D-QSAR Model for the Analysis of MMP3 Inhibitors. Tuccinardi T, Ortore G, Santos MA, Marques SM, Nuti E, Rossello A, Martinelli A. J Chem Inf Model. 2009, 49(7):1715-1724.
39.
Rational Design, Synthesis and Pharmacological Properties of New 1,8-Naphthyridin-2(1H)-on-3-Carboxamide Derivatives as Highly Selective Cannabinoid-2 Receptor Agonists. Manera C, Saccomanni G, Adinolfi B, Benetti V, Ligresti A, Cascio M, Tuccinardi T, Lucchesi V, Martinelli A, Nieri P, Masini E, Di Marzo V, Ferrarini PL. J Med Chem 2009, 52(12):3644-3651.
38.
Docking-Based Virtual Screening: Recent Developments. Tuccinardi T. Comb. Chem. High Throughput Screen. 2009, 12(3):303-314.
37.
New Resorcinol-Anandamide “Hybrids” as Potent Cannabinoid Receptor Ligands Endowed with Antinociceptive Activity in Vivo. Brizzi A, Brizzi V, Cascio MG, Corelli F, Guida F, Ligresti A, Maione S, Martinelli A, Pasquini S, Tuccinardi T, Di Marzo V. J Med Chem 2009, 52(8):2506-2514.
36.
Computational Studies of Epidermal Growth Factor Receptor: Docking Reliability, Three-Dimensional Quantitative Structure−Activity Relationship Analysis, and Virtual Screening Studies. La Motta C, Sartini S, Tuccinardi T, Nerini E, Da Settimo F, Martinelli A. J Med Chem 2009, 52(4):964-975.
35.
Structural Evolutions of Salicylaldoximes as Selective Agonists for Estrogen Receptor Beta. Minutolo F, Bertini S, Granchi C, Marchitiello T, Prota G, Rapposelli S, Tuccinardi T, Martinelli A, Gunther J R, Carlson K E, Katzenellenbogen J A, Macchia M. J Med Chem 2009, 52(3):858-867.
34.
Dual Inhibitors of Matrix Metalloproteinases and Carbonic Anhydrases: Iminodiacetyl-Based Hydroxamate−Benzenesulfonamide Conjugates. Marques SM, Nuti E, Rossello A, Supuran CT, Tuccinardi T, Martinelli A, Santos MA. J Med Chem 2008, 51(24):7968-7979.
33.
Synthesis, modeling and RET protein kinase inhibitory activity of 3- and 4-substituted-β-carbolin-1-ones. Cincinelli R, Cassinelli G, Dallavalle S, Lanzi C, Merlini L, Botta M, Tuccinardi T, Martinelli A, Penco S, Zunino F. J Med Chem 2008, 51(24):7777-7787.
32.
Structure-Activity Relationship Studies of a New Series of Imidazo[2,1-f]purinones as Potent and Selective A3 Adenosine Receptor Antagonists. Baraldi PG, Preti D, Tabrizi MA, Romagnoli R, Saponaro G, Baraldi S, Botta M, Bernardini C, Tafi A, Tuccinardi T, Martinelli A, Varani K, Borea PA. Bioorg Med Chem 2008, 16(24):10281-10294.
31.
Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors. Tuccinardi T, Nuti E, Ortore G, Rossello A, Avramova SI, Martinelli A. Bioorg Med Chem 2008, 16(16):7749-7758.
30.
Indoles and related compounds as cannabinoid ligands. Manera C, Tuccinardi T, Martinelli A. Mini rev. Med. Chem. 2008, 8(4):370-387.
29.
Substituted Pyrazolo[3,4-b]pyridines as potent and selective A1 adenosine antagonists: synthesis, biological evaluation and development of an A1 bovine receptor model. Tuccinardi T, Schenone S, Bondavalli F, Brullo C, Bruno O, Ranise A, Zizzari A, Tintori C, Ciampi O, Trincavelli ML, Martini C, Martinelli A, Botta M. ChemMedChem 2008, 3(6):898-913.
28.
Synthesis and AT1 affinity evaluation of benzamidophenyl analogs of known AT1 receptor ligands with similar aromatic skeleton. Rapposelli S, Cuboni S, Digiacomo M, Lapucci A, Trincavelli ML, Tuccinardi T, Balsamo A. Arkivoc 2008, (ii) 268-286..
27.
Molecular modeling of adenosine receptors: new results and trends. Martinelli A, Tuccinardi T. Med. Res. Rev. 2008 28(2):247-277.
26.
Derivatives of 4-Amino-6-hydroxy-2-mercaptopyrimidine (AHMP) as Novel, Potent, and Selective A3 Adenosine Receptor Antagonists. Cosimelli B, Greco G, Ehlardo M, Novellino E, Da Settimo F, Taliani S, La Motta C, Bellandi M, Tuccinardi T, Martinelli A, Ciampi O, Trincavelli ML, Martini C. J Med Chem. 2008, 51(6):1764-1770.
25.
Monoaryl-substituted Salicylaldoximes as Ligands for Estrogen Receptor Beta. Minutolo F, Bellini R, Bertini S, Carboni Isabella, Lapucci A, Pistolesi L, Prota G, Rapposelli S, Solati F, Tuccinardi T, Martinelli A, Stossi F, Carlson K, Katzenellenbogen B, Katzenellenbogen J, Macchia M. J Med Chem. 2008, 51(5):1344-1351.
24.
Homology Modelling and Receptor-Based 3D-QSAR study of Carbonic Anhydrase IX. Tuccinardi T, Ortore G, Supuran CT, Rossello A, Martinelli A. J Chem Inf Mod. 2007, 47(6):2253-2262.
23.
5-Amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: A Versatile Scaffold to Obtain Potent and Selective A3 Adenosine Receptor Antagonists. Da Settimo F, Primofiore G, Taliani S, Marini AM, La Motta C, Simorini F,Salerno S, Sergianni V, Tuccinardi T, Martinelli A, Cosimelli B, Greco G, Novellino E, Trincavelli ML, Martini C. J Med Chem. 2007, 50(23):5676-5684.
22.
Computational Approaches on Angiotensin Receptors and their Ligands: Recent Developments and Results. Tuccinardi T, Martinelli A. Curr. Med. Chem. 2007, 14(29):3105-3121.
21.
New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. Manera C, Cascio MG, Benetti V, Allarà M, Tuccinardi T, Martinelli A, Saccomanni G, Vivoli E, Ghelardini C, Di Marzo V, Ferrarini PL. Bioorg Med Chem Lett. 2007, 17(23):6505-6510.
20.
Design, Synthesis and binding studies of new potent ligands of cannabinoid receptor (II). Brizzi A, Brizzi V, Martinelli A, Tuccinardi T, Cascio MG, Bisogno T, Di Marzo V. Bioorg Med Chem. 2007, 15(16):5406-5416.
19.
Construction and Validation of a RET TK Catalytic Domain by Homology Modeling. Tuccinardi T, Manetti F, Schenone S, Martinelli A, Botta M. J Chem Inf Mod. 2007 47(2):644-655.
18.
Matrix Metalloproteinase Inhibitors: New Challenges in the Era of Post Broad-Spectrum Inhibitors. Nuti E, Tuccinardi T, Rossello A. Curr. Pharm. Design. 2007, 13(20):2087-2100.
17.
Analysis of human Carbonic Anhydrase II: Docking Reliability and Receptor-Based 3D-QSAR study. Tuccinardi T, Nuti E, Ortore G, Supuran CT, Rossello A, Martinelli A. J Chem Inf Mod. 2007 47(2):515-525.
16.
Structure-Based Virtual screening: Identification of novel CB2 receptor ligands. Tuccinardi T, Cascio MG, Di Marzo V, Manera C, Ortore G, Saccomanni G, Martinelli A. LDDD 2007, 4(1):15-19.
15.
Design, Synthesis And Molecular Modeling Study Of Iminodiacetyl Monohydroxamic Acid Derivatives As Mmp Inhibitors. Santos AM, Marques SM, Tuccinardi T, Carelli P, Panelli L, Rossello A. Bioorg Med Chem. 2006, 14(22):7539-7550.
14.
Design, synthesis and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists. Manera C, Benetti V, Castelli MP, Cavallini T, Lazzarotti S, Pibiri F, Saccomanni G, Tuccinardi T, Vannacci A, Martinelli A, Ferrarini PL. J Med Chem. 2006, 49(16):5947-5957.
13.
Synthesis of Anthranylaldoxime Derivatives as Estrogen Receptor Ligands and Computational Prediction of Binding Modes. Tuccinardi T, Bertini S, Martinelli A, Minutolo F, Ortore G, Placanica G, Prota G, Rapposelli S, Carlson KE, Katzenellenbogen JA, Macchia M. J Med Chem. 2006, 49(16):5001-5012.
12.
Pharmacophore based receptor modeling: a novel approach to protein model optimization. The case of Adenosine A3 receptor antagonists. Tafi A, Bernardini C, Botta M, Corelli F, Andreini M, Martinelli A, Ortore G, Baraldi PG, Fruttarolo F, Borea PA, Tuccinardi T. J Med Chem. 2006, 49(14):4085-4097.
11.
GPCR modeling: methods and validation. An overview of recent developments. Martinelli A, Tuccinardi T. Exp. Opin. on Drug Disc. 2006, 1(5):459-476.
10.
Proposal of a new binding orientation for non-peptide AT1 antagonists: homology model, docking and 3D-QSAR analysis. Tuccinardi T, Calderone V, Rapposelli S, Martinelli A. J Med Chem. 2006, 49(14):4305-4316.
9.
Salicylaldoximes and anthranylaldoximes as alternatives phenol-based estrogen receptor ligands. Minutolo F, Bertini S, Martinelli A, Ortore G, Placanica G, Prota G, Rapposelli S, Tuccinardi T, Sheng S, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA, Macchia M. Arkivoc 2006, (viii) 83-94.
8.
Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides. Tuccinardi T, Martinelli A, Nuti E, Carelli P, Balzano F, Uccello-Barretta G, Murphy G, Rossello A. Bioorg Med Chem. 2006, 14(12):4260-4276.
7.
Adenosine receptor modelling. A1/A2a selectivity. Tuccinardi T, Manera C, Ortore G, Saccomanni G, Martinelli A. Eur J Med Chem. 2006, 41(3):321-329.
6.
A theoretical study to investigate D2DAR/D4DAR selectivity: receptor modeling and molecular docking of dopaminergic ligands. Ortore G, Tuccinardi T, Bertini S, Martinelli A. J Med Chem. 2006, 49(4):1397-1407.
5.
Cannabinoid CB2/CB1 selectivity. Receptor modelling and automated docking analysis. Tuccinardi T, Ferrarini PL, Manera C, Ortore G, Saccomanni G, Martinelli A. J Med Chem. 2006, 49(3):984-994.
4.
Synthesis of stable analogues of geranylgeranyl diphosphate possessing a (z,e,e)-geranylgeranyl side-chain, docking analysis and biological assays for their prenyl protein transferase inhibitory activity. Minutolo F, Bertini S, Betti L,Danesi R, Gervasi G, Giannaccini G, Martinelli A, Papini A, Peroni E, Placanica G, Rapposelli S, Tuccinardi T, Macchia M. Chem Med Chem. 2006, 1(2):218-224.
3.
1,8-Naphthyridin-4-one derivatives as new ligands of A2A adenosine receptors. Manera C, Betti L, Cavallini T, Giannaccini G, Martinelli A, Ortore G, Saccomanni G, Trincavelli L, Tuccinardi T, Ferrarini PL. Bioorg Med Chem Lett. 2005, 15(20):4604-4610.
2.
A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs. Rossello A, Nuti E, Catalani MP, Carelli P, Orlandini E, Rapposelli S, Tuccinardi T, Atkinson SJ, Murphy G, Balsamo A. Bioorg Med Chem Lett. 2005, 15(9):2311-2314.
1.
Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives. Ferrarini PL, Betti L, Cavallini T, Giannaccini G, Lucacchini A, Manera C, Martinelli A, Ortore G, Saccomanni G, Tuccinardi T. J Med Chem. 2004, 47(12):3019-3031.
